Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; mannitol; croscarmellose sodium; magnesium stearate; titanium dioxide; macrogol 8000 - lurasidone agh is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; mannitol; croscarmellose sodium; magnesium stearate; titanium dioxide; macrogol 8000 - lurasidone aghl is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; mannitol; croscarmellose sodium; magnesium stearate; titanium dioxide; macrogol 8000 - lurasidone apl is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; mannitol; croscarmellose sodium; magnesium stearate; titanium dioxide; macrogol 8000 - lurasidone appl is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Stati Uniti - Ingliż - NLM (National Library of Medicine)

sumitomo pharma america, inc. - lurasidone hydrochloride (unii: o0p4i5851i) (lurasidone - unii:22ic88528t) - lurasidone hydrochloride 20 mg - latuda is indicated for: - treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see clinical studies (14.1)] . - monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar i disorder (bipolar depression) [see clinical studies (14.2)] . - adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar i disorder (bipolar depression) [see clinical studies (14.2)] . - known hypersensitivity to lurasidone hcl or any components in the formulation. angioedema has been observed with lurasidone [see adverse reactions (6.1)] . - strong cyp3a4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see drug interactions (7.1)]. - strong cyp3a4 inducers (e.g., rifampin, avasimibe, st. john's wort, phenytoin, carbamazepine, etc.) [see drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposu

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: citric acid; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; mannitol; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; mannitol; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; citric acid; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; lactose monohydrate; magnesium stearate; povidone; croscarmellose sodium; mannitol; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; mannitol; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).